<DOC>
	<DOCNO>NCT00593905</DOCNO>
	<brief_summary>Our goal determine clinically Pulmonary Arterial Hypertension patient association exist efficacy toxicity sitaxsentan , bosentan , ambrisentan several gene polymorphism several key disease-specific therapy specific gene . Also characterize relationship polymorphism severity Pulmonary Arterial Hypertension use either baseline hemodynamic clinical surrogate disease severity . Hypothesis : Polymorphisms influence efficacy toxicity specific Pulmonary Arterial Hypertension therapy well development/severity PAH via effect PA remodeling , drug response , metabolism . This study require one time 8.5 ml blood sample clinical data obtain initiation therapy , 4 month initiation therapy 12 month initiation therapy .</brief_summary>
	<brief_title>Pharmacogenomics Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>This study make use large population well define patient Pulmonary Arterial Hypertension enrol Encysive Pharmaceutical 's STRIDE clinical trial receive bosentan ambrisentan 4 month longer . This international study constitute large clinical study deadly disease great potential alter clinical practice reveal novel gene-drug interaction . This study test hypothesis execute follow aim : Aim 1 : Determine Pulmonary Arterial Hypertension ( relationship know disease-specific polymorphism ( Serotonin transporter gene PAI HindIII ) variant BMPR2 SMAD4 several well-defined clinical efficacy endpoint sitaxsentan , bosentan , ambrisentan therapy . Aim 2 : Determine Pulmonary Arterial Hypertension relationship exist potentially `` therapy-specific '' polymorphisms ET-1 , ETAR , ETBR , NPR-C , prostacyclin receptor prostacyclin synthase several well-defined clinical efficacy endpoint sitaxsentan , bosentan , ambrisentan therapy . Aim 3 : Characterize relationship treatment effect , polymorphisms PAH severity , use either clinical data clinical surrogate disease activity . ***This study fund NIH 2005 - 2009 . In August 2009 no-cost extension grant study continue end July 2010 . Currently study still active still several active site participate ; however , study fund internal institution contribute federal funding . ***</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>GROUP 1 Patients currently enrol previously enrol STRIDE FPH01 , FPH01XC FPH02 , FPH02x , FPH03 , FPH04 FPH06 . WHO Group 1 Pulmonary Arterial Hypertension : Idiopathic , Familial , Associated ( APAH ) Collagen vascular disease , congenital systemictopulmonary shunt , portal hypertension , Drugs toxins ( e.g. , anorexigens , rapeseed oil , Ltryptophan , methamphetamine , cocaine ) , ( thyroid disorder , glycogen storage disease , Gaucher disease , hereditary hemorrhagic telangiectasia , hemoglobinopathy , myeloproliferative disorder , splenectomy ) Associated significant venous capillary involvement , Pulmonary venoocclusive disease , Pulmonarycapillary hemangiomatosis . GROUP 2 Patients currently receive bosentan ambrisentan OR previously receive bosentan ambrisentan great 4 ( four ) month . WHO Group 1 Pulmonary Arterial Hypertension : Idiopathic , Familial , Associated ( APAH ) , collagen vascular disease , congenital systemictopulmonary shunt , portal hypertension , drug toxin ( e.g. , anorexigens , rapeseed oil , Ltryptophan , methamphetamine , cocaine ) , ( thyroid disorder , glycogen storage disease , Gaucher disease , hereditary hemorrhagic telangiectasia , hemoglobinopathy , myeloproliferative disorder , splenectomy ) , associate significant venous capillary involvement , pulmonary venoocclusive disease , pulmonary capillary hemangiomatosis . GROUP 1 Not enrol Encysive Pharmaceutical 's STRIDE study ( sitaxsentan ) . Known infectious disease ( HIV , Hepatitis ) . GROUP 2 Never enrol STRIDE study sitaxsentan patient . Not currently previously bosentan ambrisentan . Patients previously bosentan ambrisentan must bosentan ambrisentan great 4 month . Known infectious disease ( HIV , Hepatitis ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Pharmacogenomics</keyword>
	<keyword>DNA Testing</keyword>
	<keyword>sitaxsentan</keyword>
	<keyword>bosentan</keyword>
	<keyword>ambrisentan</keyword>
	<keyword>elevate pulmonary artery pressure</keyword>
	<keyword>Letairis</keyword>
	<keyword>Tracleer</keyword>
	<keyword>Thelin</keyword>
	<keyword>Primary Pulmonary Hypertension</keyword>
	<keyword>Pulmonary Artery</keyword>
</DOC>